![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Enzymotec Ltd. - Ordinary Shares (delisted) | NASDAQ:ENZY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.85 | 0.05 | 199,999.95 | 0 | 01:00:00 |
Israel
|
Not Applicable
|
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
Identification Number)
|
Colin J. Diamond, Esq.
White & Case LLP
1155 Avenue of the Americas
New York, NY 10036
Tel: (212) 819-8200
Fax: (212) 354-8113
|
Ron Mosberg
, Adv.
Enzymotec Ltd.
Sagi 2000 Industrial
Area, Migdal Ha'Emeq,
P.O. Box 6, 2310001,
Israel
Tel: +972-7-47177177
Fax: +972-7-47177001
|
Dan Shamgar, Adv.
David S. Glatt, Adv.
Meitar Liquornik Geva
Leshem Tal
16 Abba Hillel Silver Rd.
Ramat Gan 5250608, Israel
Tel: +972-3-610-3100
Fax: +972-3-610-3111
|
Large accelerated filer
|
¨
|
|
Accelerated filer
|
þ
|
||
Non-accelerated filer
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
¨
|
Title of Securities to be
Registered
|
Amount to be
Registered (1) |
Proposed Maximum
Offering Price per Share |
Proposed Maximum
Aggregate Offering Price |
Amount of
Registration Fee |
|||||||||||||
Ordinary Shares, par value New Israeli Shekel (“
NIS
”)
0.01 per share (“
Ordinary Shares
”)
|
911,418
|
(2)
|
$
|
9.05
|
(3)
|
$
|
8,248,333
|
(3)
|
$
|
955.98
|
(3)
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “
Securities Act
”), this Registration Statement also covers such indeterminate number of Ordinary Shares as may be offered or issued to prevent dilution resulting from stock splits, stock dividends, or similar transactions pursuant to the terms of the Enzymotec Ltd. 2013 Omnibus Equity Incentive Plan (the “
2013 Plan
”).
|
(2) |
Represents automatic increases to the number of shares available for issuance under the 2013 Plan pursuant to the “evergreen” provision under the 2013 Plan, effective January 1, 2016 and January 1, 2017
.
|
(3) |
Calculated in accordance with Rule 457(h)(1) and 457(c) promulgated under the Securities Act, based on the average of the high and low prices (which was $9.15 and $8.95, respectively) of
the registrant’s Ordinary Shares on the NASDAQ Global Select Market on March 13, 2017.
|
(a) |
Our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the Commission on March 16, 2017 pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the “
Exchange Act
”); and
|
(b) |
The information contained in our Current Report of Foreign Private Issuer on Form 6-K furnished to the Commission on March 9, 2017; and
|
(c) |
The description of our Ordinary Shares under “Item 1. Description of Registrant’s Securities to be Registered” in our registration statement on Form 8-A, filed with the Commission on September 17, 2013.
|
Exhibit
Number
|
Exhibit
|
5
|
Opinion of Meitar Liquornik Geva Leshem Tal as to the legality of Enzymotec Ltd.’s Ordinary Shares being registered
|
23.1
|
Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm
|
23.2
|
Consent of Meitar Liquornik Geva Leshem Tal (included in Exhibit 5)
|
24
|
Power of Attorney (included on the signature page of this Registration Statement)
|
99.1
|
Enzymotec Ltd. 2013 Omnibus Equity Incentive Plan (1)
|
|
|
(1)
|
Incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registrant’s Registration Statement on Form F-1 (Commission File No. 333-190781) filed with the Commission on September 16, 2013.
|
|
Enzymotec Ltd.
By:
/s/ Ariel Katz
Name: Ariel Katz Title: Chief Executive Officer |
Signature
|
Title
|
Date
|
||
/s/ Ariel Katz
Ariel Katz |
Chief Executive Officer (Principal Executive Officer)
|
March 16, 2017
|
||
/s/ Oren Bryan
Oren Bryan |
Chief Financial Officer (Principal Financial and Accounting Officer)
|
March 16, 2017
|
||
/s/ Steve Dubin
Steve Dubin |
Chairman of the Board
|
March 16, 2017
|
||
/s/ Nir Belzer
Nir Belzer |
Director
|
March 16, 2017
|
||
Tamar Howson
|
Director
|
|||
/s/ Holger Liepmann
Holger Liepmann |
Director
|
March 16, 2017
|
||
/s/ Dov Pekelman
Dov Pekelman |
Director
|
March 16, 2017
|
||
/s/ Yossi Peled
Yossi Peled |
Director
|
March 16, 2017
|
||
/s/ Michal Silverberg
Michal Silverberg |
Director
|
March 16, 2017
|
||
/s/ Joseph Tenne
Joseph Tenne |
Director
|
March 16, 2017
|
||
/s/ Mani Wasserman
Mani Wasserman |
Director
|
March 16, 2017
|
Exhibit
Number
|
Exhibit
|
5
|
Opinion of Meitar Liquornik Geva Leshem Tal as to the legality of Enzymotec Ltd.’s Ordinary Shares being registered
|
23.1
|
Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm
|
23.2
|
Consent of Meitar Liquornik Geva Leshem Tal (included in Exhibit 5)
|
24
|
Power of Attorney (included on the signature page of this Registration Statement)
|
99.1
|
Enzymotec Ltd. 2013 Omnibus Equity Incentive Plan (1)
|
|
|
(1)
|
Incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registrant’s Registration Statement on Form F-1 (Commission File No. 333-190781) filed with the Commission on September 16, 2013.
|
1 Year ENZYMOTEC LTD. Chart |
1 Month ENZYMOTEC LTD. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions